Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NXGL 
Nexgel Inc (NXGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NXGL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.56% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.77M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 2.10 - 5.10 | Updated Date 08/29/2025 |
52 Weeks Range 2.10 - 5.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.05 | Actual -0.09 |
Profitability
Profit Margin -25.02% | Operating Margin (TTM) -22.05% |
Management Effectiveness
Return on Assets (TTM) -19.51% | Return on Equity (TTM) -60.47% |
Valuation
Trailing PE - | Forward PE 41.84 | Enterprise Value 21695571 | Price to Sales(TTM) 1.69 |
Enterprise Value 21695571 | Price to Sales(TTM) 1.69 | ||
Enterprise Value to Revenue 1.78 | Enterprise Value to EBITDA -0.85 | Shares Outstanding 8067580 | Shares Floating 6838726 |
Shares Outstanding 8067580 | Shares Floating 6838726 | ||
Percent Insiders 15.59 | Percent Institutions 8.9 |
Upturn AI SWOT
Nexgel Inc
Company Overview
History and Background
Nexgel, Inc. is a hydrogel technology company developing, manufacturing, and distributing high water content, cross-linked polymer networks. The company was founded in 2011, focusing on advanced hydrogel solutions for various applications, including wound care, cosmetics, and drug delivery. Milestones include developing proprietary hydrogel formulations and scaling manufacturing capabilities.
Core Business Areas
- Advanced Wound Care: Development and sale of hydrogel-based wound dressings for acute and chronic wounds.
- Consumer Products: Formulation and marketing of hydrogel products for skin care and personal care applications.
- Contract Manufacturing: Production of hydrogel-based products for other companies under contract.
Leadership and Structure
Adam Levy is the Chief Executive Officer and Director. The company operates with functional departments including Research and Development, Manufacturing, Sales and Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Advanced Wound Care Dressings: Hydrogel dressings for burns, ulcers, and surgical wounds. Competing companies are Smith & Nephew (SNN), Molnlycke, and 3M (MMM). Nexgel competes in the advanced wound care market, where revenues are estimated at $12 Billion. Nexgel has yet to fully establish itself, revenue estimates not available.
- Hydrogel Masks: Hydrating and soothing facial masks. Competitors include L'Oreal (OR), Procter & Gamble (PG), and Estee Lauder (EL). Nexgel faces intense competition in a large and fragmented market. No reliable market share data available.
Market Dynamics
Industry Overview
The hydrogel market is growing, driven by increasing demand for advanced wound care, drug delivery, and cosmetic applications. Key trends include the development of biocompatible and biodegradable hydrogels.
Positioning
Nexgel aims to differentiate itself through proprietary hydrogel formulations and advanced manufacturing capabilities. Its competitive advantage lies in its focus on high-performance hydrogels.
Total Addressable Market (TAM)
The global hydrogel market is estimated at around $35 billion and growing. Nexgel is relatively small with respect to the TAM but is positioning itself for growth with advanced formulations.
Upturn SWOT Analysis
Strengths
- Proprietary hydrogel formulations
- Advanced manufacturing capabilities
- Focus on high-performance applications
Weaknesses
- Limited brand recognition
- Small market share
- Reliance on key personnel
- Limited financial resources
Opportunities
- Expanding into new applications
- Partnerships and collaborations
- Geographic expansion
- Increasing demand for advanced wound care
Threats
- Competition from larger players
- Regulatory changes
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- 3M (MMM)
- L'Oreal (OR)
Competitive Landscape
Nexgel faces strong competition from established players with greater resources and brand recognition. Nexgel needs to differentiate through innovation and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data unavailable.
Future Projections: Future growth projections are not publicly available, but analyst estimate an upward trend, however they are subject to market performance.
Recent Initiatives: Recent initiatives include expanding product lines and seeking partnerships to broaden market reach.
Summary
Nexgel Inc. is a growing company in the hydrogel technology sector, with proprietary formulations and advanced manufacturing capabilities. However, it faces stiff competition from larger, more established players. Strategic partnerships and continued innovation are crucial for sustained growth. Limited financial resources and brand recognition represent significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Analysis
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexgel Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2021-12-22 | CEO, President & Director Mr. Adam R. Levy | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 19 | Website https://nexgel.com |
Full time employees 19 | Website https://nexgel.com | ||
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.